Annick Desjardins

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Annick Desjardins sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 6 completed early-phase tilt top decile by trial count

Annick Desjardins: 9 sponsored US clinical trials, none currently recruiting.

Annick Desjardins sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gliosarcoma, with 1 trials.

Top-decile sponsor footprint

Annick Desjardins ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

COMPLETED Phase 2

Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma

NCT02540161
TERMINATED Phase 1

Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma

NCT01989052
TERMINATED Phase 1

Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure

NCT01954030
TERMINATED Phase 2

Panitumumab and Irinotecan for Malignant Gliomas

NCT01017653
COMPLETED Phase 1

Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma

NCT00979173
COMPLETED Phase 2

Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)

NCT00953121
COMPLETED Phase 1

Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas

NCT00613223
COMPLETED Phase 1

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

NCT00613054
COMPLETED Phase 1

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

NCT00613132

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 3

Therapeutic Areas

Gliosarcoma 1
Malignant Glioma 1
Glioblastoma 1
Glioma 1

How the Annick Desjardins early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 6 completed (67%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Gliosarcoma (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Annick Desjardins: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Annick Desjardins sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Annick Desjardins4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Annick Desjardins sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Annick Desjardins sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Annick Desjardins page

9 registered trials is a research-attention snapshot, not an endorsement of Annick Desjardins or any single study.

  • None of Annick Desjardins's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Gliosarcoma is the condition Annick Desjardins studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gliosarcoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Annick Desjardins pipeline card: 9 registered trials from official public datasets.Report a data error.